Session one: Understanding ADCs – The fundamentals and emerging innovations

The opening session will address the ADC landscape, exploring historical development, mechanisms, and emerging medical applications. Hear how Victorian innovators are progressing ADC R&D and overcoming local and global commercialisation barriers.

 

Chair: Brittany Ashton

Senior Associate, FB Rice

Brittany Ashton is a senior associate in our Melbourne chemistry team.

Brittany specialises in medicinal chemistry and pharmaceuticals with expertise in small molecules, organic syntheses, methods of treatment, formulations, combinations, and dosage regimens. She has a particular interest in the emerging areas of radiopharmaceuticals and antibody-drug conjugates. Brittany takes a holistic approach to managing clients’ intellectual property portfolios, drawing upon her scientific expertise, in-depth knowledge of the relevant patent laws in various jurisdictions, and commercialisation acumen. Her clients value her ability to relay complex strategic advice with clear and concise communication.

Brittany was awarded Best IP Specialist at the Client Choice Awards 2021, acknowledged by MIP IP STARS as a Notable Practitioner in 2020, and an MIP Rising Star in 2019.

 

Prof. Christoph Hagemeyer

Director, Monash Biomedical Imaging 

Christoph Hagemeyer is the Director of Monash Biomedical Imaging (MBI). He is also the Monash University Node Director of the Victorian Biomedical Imaging Capability, Node Director of the Australian National Imaging Facility and the Principal Investigator of the Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics.

Prof Hagemeyer studied Chemistry in Germany and obtained a PhD in Biochemistry from the University of Freiburg (Germany) for contributions to the field of Cytochrome P450 metabolism in the brain. As a postdoctoral fellow, he worked in the field of Magnetic Resonance Imaging (MRI) at the “Centre national de la recherche scientifique” in Bordeaux (France) before migrating to Australia in 2005. He has particular expertise in the use of small recombinant single-chain antibodies for molecular imaging and drug delivery. He has work extensively in cardiovascular research developing anti-thrombotic fusion proteins and novel imaging probes for MRI, Ultrasound and Positron Emission Tomography. He has published widely in leading journals (Circ Res, Adv Mater, Angew Chem..) on vascular biology, molecular imaging, recombinant antibodies, and nanotechnology. Prof Hagemeyer has attracted high-quality postgraduate students and postdoctoral fellows and has supervised over 30 postgraduate and post-doctoral students. He has been supported throughout his career by national and international fellowships and grants.

 

Dr Michael Wheatcroft

Chief Scientist, Telix Pharmaceuticals

Dr Wheatcroft is Director of R&D at Telix. After completing a PhD in the Department of Biochemistry, Cambridge University, Mike worked at Cambridge Antibody Technology (now Medimmune,UK), a technology leader in the area of antibody engineering and protein sciences. After moving to Melbourne in 2010 he oversaw the preclinical development of several engineered antibody drug conjugates and clinical translation of novel antibody fragment in prostate and ovarian cancer, including radioimmunoconjugates. Since then Mike has worked in senior development roles at Medicines Development Limited (MDL), Hatchtech P/L and Starpharma Limited where he performed in a variety of managerial roles related to GMP production, clinical study support and nonclinical studies for a range of pharmaceutical and medical device products.

 

 

Dr Charlotte Williams

Principal Research Scientist, Group Leader | Chemical Biology, Diagnostics and Devices, CSIRO Manufacturing

Dr Williams is a Principal Research Scientist within the Biomedical Manufacturing Program at CSIRO and Group Leader for Chemical Biology, Diagnostics and Devices.

With an expertise and track record in areas such as synthetic chemistry, bioconjugation of small molecules and polymers to proteins and antibodies, as well as polymer synthesis and polymer bioconjugation; Dr Williams engages with SMEs, industry, and academia to develop new products and processes for the biomedical sector.

Dr Williams has instigated ongoing research areas such as: theranostic cancer imaging, therapeutic Antibody-Drug-Conjugates, development of new biocatalysts for the pharmaceutical industry, development of hydrogel materials and drug-delivery polymers for various therapeutic indications.

Through the Biomedical Manufacturing Program Dr Williams assists Australian SME Biotech and MedTech companies in their growth strategies.

 Category: Sector Events

Home

News & opinion

Member Directory

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.

Copyright © BioMelbourne Network Network

Website by Silver Lane Studio